GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (FRA:1UC) » Definitions » Sale Of Investment

Cue Biopharma (FRA:1UC) Sale Of Investment : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Sale Of Investment?

Cue Biopharma's sale of investment for the three months ended in Sep. 2024 was €0.00 Mil. It means Cue Biopharma gained €0.00 Mil from selling investments. Cue Biopharma's sale of investment for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Jun. 2024 ), Cue Biopharma gained the same money from selling investments in Sep. 2024 (€0.00 Mil).


Cue Biopharma Sale Of Investment Historical Data

The historical data trend for Cue Biopharma's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Sale Of Investment Chart

Cue Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only 16.65 12.33 8.85 4.72 22.93

Cue Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.69 - - - -

Cue Biopharma Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cue Biopharma Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Cue Biopharma Business Description

Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Cue Biopharma Headlines

No Headlines